The Raptor Pharmaceutical Inc. business is the discovery, research and preclinical development of novel drug candidates and drug-targeting platforms intended to treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP) and mesoderm development (Mesd). The main purpose of Raptor Inc. will be to move drug product candidates through the early phases of drug discovery and preclinical proof-of-principle studies, a critical component to building a strong pipeline of potential drug candidates. Once these early studies are complete, drug candidates may be partnered, out-licensed or further developed into the clinical phase by Raptor Inc.’s sister company, Bennu Pharmaceuticals Inc.

Acquired Companies: TorreyPines Therapeutics Inc., Encode